The key equity benchmarks pared early gains in morning trade. The Nifty was trading below the 17,350 mark. Pharma shares were up across the board.
At 10:20 IST, the barometer index, the S&P BSE Sensex, was up 107.25 points or 0.18% to 58,096.55. The Nifty 50 index added 33.90 points or 0.20% to 17,349.40.
In the broader market, the S&P BSE Mid-Cap index rose 0.53% while the S&P BSE Small-Cap index gained 0.59%.
Buyers outnumbered sellers. On the BSE, 1961 shares rose and 1104 shares fell. A total of 133 shares were unchanged.
Buzzing Index:
The Nifty Pharma index rose 1.49% to 13,714.50. The index had declined 0.27% to end at 13,513.15 yesterday.
Pfizer (up 3.37%), Torrent Pharma (up 3%), Dr. Reddy's Labs (up 2.84%), Aurobindo Pharma (up 2.39%) and Divi's Labs (up 2.35%) were the top index gainers.
Concurrently, Strides Pharma (up 2.29%), Glenmark Pharma (up 2.28%), Zydus Lifesciences (up 1.96%), Lupin (up 1.62%), Biocon (up 1.36%), Cipla (up 1.06%), Ipca Laboratories (up 1.04%), Sun Pharma (up 0.94%) and Abbott India (up 0.84%) advanced.
Stocks in Spotlight:
RailTel Corporation of India gained 1.90% to Rs 91.30. The company has received work order from Rail Vikas Nigam Limited (RVNL) for installation of RailTel''s MPLS-VPN services for 5 years at various locations of RVNL for an amount of Rs. 11.57 crore (Including GST).
Ugro Capital fell 1.19% to Rs 182.85. The company said that a meeting of the Investment and Borrowing Committee of the board is scheduled on Friday, 25 March 2022 to consider and approve raising of funds via issuance of Non-Convertible Debentures (NCDs) on private placement basis.
Indian Hotels Company advanced 0.96% to Rs 210.75. The board of the hospitality company authorized opening the qualified institutional placement (QIP) issue of Rs 2000 crore on Tuesday, 22 March 2022. Floor price is set at Rs 203.48. The board is scheduled to meet on 25 March 2022 to approve the issue price.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU